The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Book Review
PreviousPrevious
Volume 341:2023-2024 December 23, 1999 Number 26
NextNext

Clinical Management of Bladder Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
Edited by Reginald R. Hall. 384 pp., illustrated. London, Arnold, 1999. (Distributed by Oxford University Press, New York.) $95. ISBN 0-340-74092-2.

A little over 100 years ago, Rehn made the seminal observation that there was a high incidence of bladder cancer among workers exposed to aniline dyes. The subsequent identification of the carcinogens used in the manufacture of these dyes led to the first successful control of cancer by epidemiologic means. In the United States, in 1998 there were 54,000 cases of cancer of the bladder and 12,500 deaths from this disease. The wide discrepancy between incidence and mortality is accounted for by the prevalence of superficial tumors. Such tumors frequently recur, but only 20 percent progress and invade the bladder . . . [Full Text of this Article]




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.